Miguel Pascual Bernáldez

Statistics

Publications

Citations

197

H-Index

Active since

2020

Affiliations

ViiV Healthcare (Spain)(Current)

Georgetown University

ViiV Healthcare (United Kingdom)

Triangle

Complejo Hospitalario Universitario de Santiago

Miguel Pascual Bernáldez is an author at ViiV Healthcare (Spain) specializing in long-acting antiretroviral therapy, antiretroviral therapy, and hiv antiretroviral therapy.

Publications per year

2020–2023

Publications

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

Moti Ramgopal, Antonella Castagna, Charles Cazanave et al. · The Lancet HIV · 2023 · 115 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials

Andrea Mantsios, Miranda Murray, Tahilin Sanchez Karver et al. · BMC Health Services Research · 2021 · 53 citations · Full text

Public Health, Health Sciences, Evidence-based Practice +16

“I feel empowered”: women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain

Andrea Mantsios, Miranda Murray, Tahilin Sanchez Karver et al. · Culture Health & Sexuality · 2020 · 29 citations

Public Health, Gender Studies, Hiv Prevention +11

1–3 of 3